Loading patent…
AssigneesMitsubishi Pharma Corporation, Sidem Pharma
InventorsFrançois Schutze, Suzy Charbit, Hervé Ficheux, Michel Homerin, Alain Taccoen, Nathalie Taccoen, Yoshio Inaba
Estimating the term…
The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophageal reflux.
A pharmaceutical composition for the treatment of a disease related to gastric hyperacidity, said composition comprising tenatoprazole and one or more histamine H2-receptor antagonists.
A medicinal product useful for the treatment of a disease related to gastric hyperacidity, said product comprising tenatoprazole and at least one histamine H2-receptor antagonist.
A method of treating a disease related to gastric hyperacidity, said method comprising administering a medical product comprising tenatoprazole and at least one histamine H2-receptor antagonist.
Dependencies are inferred from the claim text.